IP05 promotes the proliferation and tumourigenicity of colorectal cancer cells by mediating RASAL2 nuclear transportation

Wenjuan Zhang¹, Yanxia Lu¹, Xiaomin Li¹, Jianming Zhang¹², Weihao Lin¹, Wei Zhang¹, Lin Zheng¹ and Xuenong Li¹*

Abstract

Background: Karyopherin nuclear transport receptors play important roles in tumour development and drug resistance and have been reported as potential biomarkers and therapeutic targets for tumour treatment. However, IP05, one of the karyopherin nuclear transport receptor family members, remains largely uncharacterized in tumour progression.

Methods: The TCGA data, quantitative reverse transcription-PCR (qRT-PCR), western blotting, and IHC analyses were used to detect IP05 expression in CRC tissues. A series of in vivo and in vitro experiments was utilized to demonstrate the function of IP05 in CRC tissues. Mass spectrometry (MS), CO-IP technology, subcellular fractionation, and immunofluorescence were utilized to investigate the possible mechanisms of CRC.

Results: IP05 was highly expressed and positively correlated with the clinicopathological characteristics of colorectal cancer tissues. Functional experiments indicated that IP05 could promote the development of CRC. Mechanistically, we screened RASAL2, one cargo of IP05, and further confirmed that IP05 bound to the NLS sequence of RASAL2, mediating RASAL2 nuclear translocation and inducing RAS signal activation, thereby promoting the progression of CRC.

Conclusions: Together, our results indicate that IP05 is overexpressed in colorectal cancer cells. By transporting RASAL2, IP05 may play a crucial role in CRC.

Keywords: Colorectal cancer, IP05, RASAL2, NLS, Ras pathway, Karyopherins

Background

Colorectal cancer has become a major threat to human health. Although a large number of studies have been performed on CRC, the concrete molecular mechanisms of the formation and metastasis of CRC has not been completely clear until recently. Therefore, an in-depth study of the molecular mechanisms of the occurrence and development of CRC and the identification of effective molecular markers among many factors is of great importance.

Karyopherins are key regulatory molecules of nuclear plasma transport and are the most classic cell transporter proteins; they include both importins and exportins [1, 2]. Transporter proteins that have molecular weights greater than 40 kDa transport a variety of molecules between the cytoplasm and nucleus through the nuclear pore complex; these include transcription factors, splicing factors and other proteins [3–5]. Nevertheless, the dysfunction of karyopherins may derail the transport activity and may cause the abnormal localization of oncogenic factors, thus leading to tumourigenesis [6–8]. The currently reported karyopherins related to tumours include KPNA2, XPO5, XPO1, and KPNA7 [9–11]. IP05, a member of the karyopherin beta subunit, locates in the 13q32 chromosomal region and has been demonstrated to play a vital role in the translocation of various proteins. However, the role of IP05 in cancer progression has not been well defined.
our previous research, we analysed the CRC gene expression profile data of GSE41258 and sifted out a number of differentially expressed genes in which the expression of IPO5 was continuously increasing with the increasing severity from normal tissues to stage I, stage II, stage III, stage IV, and liver metastasis tumors (Additional file 1: Figure S1A) [12]. Meanwhile, the high expression of IPO5, especially in CRC cells, was also confirmed in the TCGA database and Oncomine database (Additional file 1: Figure S1B). Therefore, we hypothesized that IPO5 may play a key role in the development of CRC.

RASAL2, a member of the RAS GTPase-activating protein family, plays a role in negatively regulating RAS activity by catalysing the hydrolysis of RAS-GTP to RAS-GDP. Therefore, it is a key regulator of the RAS signalling pathway and is involved in many cellular activities. RAS signalling is intimately associated with the proliferation and metastasis of CRC cells. RASAL2 was reported to exhibit pro-tumorigenic or anti-tumorigenic effects in different types of cancer. Its role in colorectal cancer remains controversial.

In this study, we determined that the expression level of IPO5 is significantly upregulated in CRC tissues. Functional assays revealed that IPO5 could promote CRC growth in vitro and in vivo, and the mechanism involved was with the mediation of RASAL2 nuclear translocation followed by the activation of the RAS signalling pathway. Our study provides a potential oncogenic role for IPO5 in CRC development.

**Methods**

**Cell culture**

Cell lines SW620, SW480, HCT116, LoVo, HT-29, LS 174 T, Caco-2, RKO were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in RPMI 1640 medium (Gibco, Grand Island, NY, USA) with 5% FBS at 37 °C with 5% CO2 (Gibco, USA). FHC cells were cultured in DMEM medium (Gibco, Grand Island, NY, USA) with 20% FBS (Gibco, Grand Island, NY, USA) at 37 °C in a humidified atmosphere with 5% CO2.

**Clinical specimens and animals**

Human colorectal cancer tissues specimens were collected from patients with general surgery in Nanfang Hospital, Southern Medical University (Guangzhou, China), with informed consent from all patients. The fresh surgically resected CRC tissues were immediately frozen in liquid nitrogen and were stored at −80 °C until further use. The use of clinical materials for research purposes has been approved by the Southern Medical University Institutional Board (Guangzhou, China). Female, 4–5 weeks old BALB/C nude mice were purchased from the Animal Center of Guangdong Province. All nude mice were raised under SPF conditions.

**RNA extraction and real-time quantitative PCR**

The total RNA was extracted according to the instructions of Trizol reagent (Takara), and RNA reverse transcription were performed using Takara Reversal Kit. Quantitative real-time PCR (qRT-PCR) was done using the SybrGreen Qpcr Mix (DBI Bioscience). Relative expression levels were detected on ABI PRISM7500 Sequence Detection System (Applied Biosystem) [13]. The primer sequences are listed in Additional file 6: Table S4.

**Immunohistochemistry**

Immunohistochemistry staining and scoring were performed according to previous research [13]. IPO5 (Bioss, Beijing; #bs-17075R), Ki67 (zsgb-bio, Beijing; #ZA-0502) and RASAL2 (Bioss, Beijing; #bs-21160R) antibodies were used for immunostaining.

**Construction of plasmids and transfection**

The lentiviral constructs expressing or repressing IPO5 were purchased from Genechem (Shanghai, China), and the IPO5 siRNA was synthesized by Ribobio (Guangzhou, China). The RASAL2 wild type and RASAL2-NLS mutant plasmids were purchased from GeneCopoeia (USA). Cell transfection was performed using Lipofectamine 3000 as described in the manufacturer’s protocol (Invitrogen, USA).

**Western blot assay**

The total protein was extracted using a lysis buffer (KeyGen Biotech, Nanjing, China) and the protein concentration was determined by bicinchoninic acid quantification kit (KeyGen Biotech, Nanjing, China). The protein was separated with 10% SDS-PAGE, and transferred onto PVDF membrane. Specific primary antibody was added: anti-GAPDH (proteintech, USA, #10494–1-AP), anti-p21 (Abcam, Cambridge, USA, #ab109199), anti-p27 (Abcam, Cambridge, USA, #ab92741), anti-cyclinD1 (proteintech, USA, #60186-1-lg), anti-p53 (proteintech, USA, #60283-2-lg), anti-PARP (Cell Signaling, Beverly, MA, #9542), anti-p-PARP (Cell Signaling, Beverly, MA, #9548), anti-Caspase-3 (Cell Signaling, Beverly, MA, #9662), anti-p-Caspase-3 (Cell Signaling, Beverly, MA, #9664), anti-Akt (Cell Signaling, Beverly, MA, #9279), anti-p-Akt (Ser-473) (Cell Signaling, Beverly, MA, #4060), anti-Erk (Cell Signaling, Beverly, MA, #4370), anti-p-Erk1/2 (Cell Signaling, Beverly, MA, #4370), anti-CDK4 (proteintech, USA, #11026–1-AP), anti-CDK6 (proteintech, USA, #14052–1-AP), anti-myc (Abcam, Cambridge, USA, #ab32072), anti-bax (Abcam, Cambridge, USA, #ab32503), anti-bcl2 (Abcam, Cambridge, USA, #ab32124) and incubated at 4 °C overnight.
followed by incubation with their respective second antibodies. The bands were visualized using Pierce ECL Western Blotting Substrate (Thermo Scientific, USA).

**Nude mice tumorigenicity assay**

Female BALB/c nude mice aged 4–5 weeks were used and all animal experimental protocols were reviewed and approved by the Animal Care and Use Committee of Southern Medical University. In briefly, 1 × 10⁷ cells suspended in PBS were injected subcutaneously in the back of nude mice (n = 7 per group). The diameter of the tumor was measured every 3–4 days, tumor volume was calculated (V = 1/2*length*width*height). After 4 weeks, the tumor was excised and fixed in 10% formalin, followed by haematoxylin–eosin (HE) staining.

**CCK-8 cell proliferation, colony formation and transwell assay**

Cell proliferation, colony formation assay, transwell migration assays were performed as previous described [13].

**Flow cytometry**

The Cell Cycle Detection Kit (KeyGEN, Nanjing) and Fluorescein isothiocyanate (FITC), Annexin V, propidium iodide Apoptosis Detection Kit (KeyGEN, Nanjing) were used according to the manufacturer's instruction.

**Subcellular fractionation**

The nuclear plasma separation kit was purchased from TransGen Biotech (Beijing) and was carried out according to the instructions. Western blotting was used to verify the extraction. GAPDH antibody (proteintech, USA, #10494–1-AP) was used as cytoplasmic internal reference and Lamin B antibody (proteintech, USA, #23498–1-AP) was used as nuclear internal reference.

**Co-immunoprecipitation**

Appropriate volume of IPO5 and RASAL2 antibodies (Santa Cruz Biotechnology, USA; #sc-390,605) were added to the extracted cell lysate and the mixture was shaken slowly overnight at 4 °C. Subsequent steps were performed as previous described and proteins was detected by western blot [14].

**Immunofluorescence**

Cells were fixed and permeabilized with 0.5% TritonX-100, followed by blocked with 1% BSA for 30 min at room temperature. Thereafter, the primary anti-IPO5 (Santa Cruz Biotechnology; #sc-55,527) and RASAL2 (Santa Cruz Biotechnology; #sc-390,605) were added and incubated at 4 °C overnight. The next steps are the same as previous studies [14].

**Statistical analysis**

SPSS 20.0 software (IBM) was used for data analysis. All data were presented as mean ± SD, comparison between groups using one-way ANOVA or independent t-test. The relationships between IPO5 expression and clinical pathological parameters were determined by χ² test. Relationships between IPO5 expression and RASAL2 nuclear location were analysed by χ² test. *p < 0.05, **p < 0.01, ***p < 0.001 was considered statistically significant.

**Results**

**IPO5 is upregulated in colorectal cancer tissues**

The overexpression of IPO5 at the mRNA and protein levels was further verified using quantitative reverse transcription-PCR (qRT-PCR) and western blotting in 40 and 8 pairs of primary CRC and normal tissues, respectively (Fig. 1a-c). By evaluating the expression levels of IPO5 in eight colorectal cancer cell lines, LOVO, FHC, CACO2, RKO, SW620, SW480, HT29 and HCT116, we found that compared with that in the normal epithelial cell line FHC, IPO5 is highly expressed in cancer cells, and the highest expression levels were found in SW620, a cell line with high metastatic potential (Fig. 1d). To further investigate the potential clinical significance of IPO5 in CRC, we constructed ROC curves, using the relative expression levels of IPO5 in CRC tissues and paired non-cancerous tissues (AUC of 0.9050) (Fig. 1e). The data indicate IPO5 has potential as a biomarker for CRC diagnosis. Furthermore, the immunohistochemistry results showed that IPO5 is located predominantly in the cytoplasm and the positive staining of IPO5 was significantly higher in the cancer tissues than it was in the corresponding normal tissues (Fig. 1f). To further evaluate the relationship between the expression levels of IPO5 and the clinicopathological parameters, the expression of IPO5 was divided into a low-level group (n = 47) and a high-level group (n = 53). The results showed that the positive protein expression of IPO5 was positively correlated with tumour size, differentiation, TNM stage, lymph node metastasis (Table 1).

**Knockdown of IPO5 inhibits the growth and migration of CRC cells in vitro and in vivo**

To characterize the biological role of IPO5 in CRC cells, we overexpressed IPO5 in the SW480 and HCT116 cell lines, simultaneously silenced IPO5 expression with IPO5-shRNA in SW620 and RKO cells (Fig. 2a), and then selected IPO5-shRNA1 to construct lentiviral stable interfering IPO5 cell lines for subsequent functional studies. The upregulation of IPO5 significantly increased the activity (P < 0.01) and clonogenicity (P < 0.01) of HCT116 and SW480 cells compared to those of the normal control cells (Additional file 2; Figure S2A and S2B). Conversely, interference with IPO5 reduces cell viability...
(P < 0.01) and clonal formation (P < 0.01) (Fig. 2b). The cell cycle distribution was detected by flow cytometry. The results showed that the overexpression of IPO5 increased the proportion of G1 phase cells and decreased the proportion of G2/M phase cells (Additional file 2: Figure S2C). In contrast, the silencing of IPO5 resulted in the opposite result (Fig. 2c). Therefore, IPO5 can induce G2-M phase transition in CRC cells. We used
western blotting to detect the effects of IPO5 on cell cycle-related proteins; the results showed that the overexpression of IPO5 significantly upregulated the expression of CyclinD1, CDK4, CDK6 and Myc and down-regulated the expression of p53, p21, p27 and the opposite results were obtained after interference with IPO5 (Fig. 2d). We then examined the effects of IPO5 on the apoptosis of CRC cells induced by 5-fluorouracil. The results showed that IPO5 depletion sensitized CRC cells to 5-fluorouracil treatment as detected by increased apoptotic rates \( (P < 0.01) \) (Fig. 2e) and elevated apoptotic marker expression levels (Fig. 2f). Thus, we estimate that IPO5 may be associated with 5-fluorouracil resistance in CRC. Next, the effect of IPO5 on cell motility was measured by a transwell assay. The ectopic expression of IPO5 significantly promoted cell migration compared to that in the control cells \( (P < 0.05) \) (Fig. S2D). The opposite results were obtained in cells with the repression of IPO5 \( (P < 0.01) \) (Fig. 2g). To confirm the tumourigenic ability of IPO5 in vivo, RKO-shNC and RKO-shIPO5 cells were subcutaneously injected into nude mice. As shown in the figure, IPO5 down-regulation markedly reduced the size of RKO xenografts in nude mice (Fig. 2h). Coincidently, fewer proliferating cells were detected in RKO-shIPO5 xenografts, as indicated by the Ki-67 assay \( (P < 0.01) \) (Fig. 2i).

### Upregulation of IPO5 correlates with 5-fluorouracil resistance in CRC cells

To further verify that IPO5 is associated with 5-fluorouracil resistance in colorectal cancer cells, we examined the effect of IPO5 overexpression on apoptosis induced by 5-FU. The results showed that cells with up-regulated IPO5 expression were less sensitive towards 5-FU-induced apoptosis compared with that of the control cells (Fig. 3a). Consistent with the apoptosis results, the colony formation in IPO5-overexpressing CRC cells was significantly higher than that in the mock cells in response to 5-fluorouracil treatment (Fig. 3b). Treatment with 5-fluorouracil increased the levels of the apoptotic markers cleaved caspase-3, and cleaved PARP. However, the upregulation of IPO5 partially reduced this effect (Fig. 3c). These results indicate that the expression of

### Table 1 Clinicopathologic characteristics of IPO5 expression in CRC patients

| Clinicopathological Variables   | N 100 | High expression 53 | Low Expression 47 | \( \chi^2 \) | \( P \) |
|---------------------------------|-------|---------------------|-------------------|-------------|--------|
| Age (years)                     |       |                     |                   |             |        |
| \( \leq 60 \)                    | 48    | 26                  | 22                | 0.050       | 0.49   |
| > 60                            | 52    | 27                  | 25                |             | 0      |
| Gender                          |       |                     |                   |             |        |
| Male                            | 56    | 28                  | 28                | 0.460       | 0.549  |
| Female                          | 44    | 25                  | 19                |             |        |
| Tumor size (cm)                 |       |                     |                   |             |        |
| \( \leq 4.75 \)                 | 49    | 21                  | 28                | 3.968       | 0.036  |
| > 4.75                          | 51    | 32                  | 19                |             |        |
| Differentiation                 |       |                     |                   |             |        |
| Well                            | 20    | 7                   | 13                | 7.647       | 0.020  |
| Moderate                        | 61    | 30                  | 31                |             |        |
| Poor                            | 19    | 16                  | 3                 |             |        |
| Serosal invasion                |       |                     |                   |             |        |
| Yes                             | 40    | 20                  | 20                | 0.241       | 0.387  |
| No                              | 60    | 33                  | 27                |             |        |
| Lymph metastasis                |       |                     |                   |             |        |
| Yes                             | 45    | 30                  | 15                | 10.389      | 0.006  |
| No                              | 55    | 23                  | 32                |             |        |
| TNM classification              |       |                     |                   |             |        |
| I–II                            | 65    | 29                  | 36                | 10.585      | 0.014  |
| III–IV                          | 35    | 24                  | 11                |             |        |

Zhang et al. Journal of Experimental & Clinical Cancer Research (2019) 38:296
Fig. 2 (See legend on next page.)
IPO5 might contribute to acquired drug resistance to 5-fluorouracil in CRC cells.

**RASAL2 represents a novel IPO5 cargo protein**

To explore the molecular mechanisms of IPO5-mediated regulation in CRC cells, we applied CO-IP technology followed by mass spectrometry (MS) to identify the proteins interacting with IPO5 (Fig. 4a). After removing the common false-positive hits, a total of 640 proteins were identified (Additional file 3: Table S1). To clarify the specific biological processes involving IPO5, 640 proteins were further examined using DAVID combined with

(See figure on previous page.)

**Fig. 2** Knockdown of IPO5 inhibits the growth and migration of colorectal cancer cells. a Overexpression or knockdown efficiency of IPO5 was confirmed by western blotting. b IPO5 knockdown significantly inhibited cell growth on the basis of CCK8 and colony formation assay. Error bars represent the means ± SD of 5 or 3 independent experiments. ***p < 0.001. c Cell cycle was detected by flow cytometry after silence IPO5 expression. d The expression levels of Cycle-related proteins were detected by western blotting. e Knockdown of IPO5 increased apoptotic cells as analyzed by flow cytometry. f Expression of apoptosis protein markers were analyzed using western blotting. g Silencing of IPO5 reduced CRC cells migration was showed by transwell assays. Error bars represent the means ± SD of 5 different fields. h p < 0.05. h IPO5 knockdown inhibited growth of RKO xenografts in nude mice (n = 7). Right panel showed the tumor sizes change. The data were calculated as the mean tumor volumes ± SD for 7 samples. i Representative images of IHC staining and Ki67-positive Sections of subcutaneous tumors. Error bars represent the means ± SD of 5 different fields.
Fig. 4

(See legend on next page.)
KEGG pathway enrichment analysis. We found that in addition to the known functionality in the database, there are also notable features of interest, such as cell cycle regulation and cytoskeletal regulation (Additional file 4: Table S2). In addition, we built biological networks and analysed the signal pathways involved in these 640 proteins by using Cytoscape software plug-in ClueGO in conjunction with the WikiPathway database, and we found that these proteins were involved in various cancer-related signal pathways (Fig. 4b). To further pinpoint potential proteins transported to the nucleus by IPO5, we used the cNLS Mapper Tool together with the COMPARTMENTS database to determine the nuclear localization signal and subcellular localization of the proteins. Finally, 15 proteins with NLS sequences and shuttles through the nucleoplasm were screened, which we believe are the most likely cargo candidates for IPO5 (Additional file 5: Table S3). From these 15 proteins, we focused on 8 cancer-related proteins (UBR5, ATRX, RASAL2, LIMK1, RAD51, RABL6, SIN3A, and DNAJB1) for further subcellular fractionation analysis. The results showed that RASAL2 was the most likely cargo protein for IPO5 in CRC cells (Additional file 2: Figure S2E). To verify our results, we continued to explore whether the subcellular localization of RASAL2 was affected by IPO5. The results showed that the amounts of cytoplasmic RASAL2 increased together with a concomitant decrease in the nuclear levels after silencing IPO5, whereas cells overexpressing IPO5 showed the opposite results (Fig. 4c). Furthermore, we performed an endogenous reciprocal CO-IP assay to verify the interaction of IPO5 and RASAL2 (Fig. 4d). Then, immunofluorescence and confocal microscopy were used to demonstrate that RASAL2 translocated into the nucleus in IPO5 upregulated cells but accumulated in the cytoplasm and at the cell surface in si-IPO5-treated cells (Fig. 4e). These results collectively suggest that IPO5 mediates RASAL2 nuclear transport in CRC cells.

**IPO5-mediated nuclear import of RASAL2 is required for RAS pathway activation and CRC development**

Given the major role of RASAL2 in regulating the RAS pathway, we investigated whether IPO5 could modulate the RAS pathway. Strikingly, western blotting showed that interference with IPO5 caused a significant decrease in p-Erk, p-Mek, and p-Akt. However, the overexpression of IPO5 causes an increase in these proteins (Fig. 6a). To further characterize whether RASAL2 contributes to this phenotype, we transfected the RASAL2-WT and RASAL2-NLS-MUT plasmids into HCT116 and SW480 cells that overexpressed IPO5, respectively, and performed a western blot analysis. The results showed that RASAL2-NLS-MUT can significantly abolish IPO5-mediated RAS signalling activation and the expression of RAS target proteins, while RASAL2-WT can only partially perform these functions (Fig. 6b). Similar to this observation, compared to that of RASAL2-NLS-WT, RASAL2-MUT more obviously abrogated the tumour-promoting function of IPO5 in vitro and in vivo, as indicated by colony formation, transwell experiments and subcutaneous tumourigenicity (Fig. 6c, d and e). Furthermore, we performed immunohistochemical staining on subcutaneous tissues to examine the relationships between nuclear RASAL2, Ki-67 and IPO5. We found that compared with that of the RASAL2-NLS-WT group, RASAL2-NLS-MUT significantly reversed RASAL2 nuclear accumulation induced by IPO5 overexpression (Fig. 6f). Similarly, by analysing several serial sections from 60 CRC patients,
we found that the RASAL2 protein was detected in the nucleus mainly in high IPO5 expression regions, while RASAL2 was restricted to cytoplasmic distribution in the low IPO5 expression sections \( (P < 0.01) \) (Fig. 6g). Finally, we concluded that IPO5-mediated RASAL2 nuclear transport is required for CRC progression.

Discussion

It has been well established that the dysfunction of karyopherins can lead to the abnormal localization of oncogenes and tumour suppressor genes and contributes to the uncontrolled growth and drug resistance of cancer cells [15, 16]. The frequently observed aberrant expression of karyopherins has been reported to be involved in multiple tumours [17–19]. For example, CRM1, KPNB1 and KPNA2 are overexpressed in cervical cancer cells [20, 21]. KPNA2 associates with glioblastomas and colon cancer [22, 23]. The abnormal expression of CRM1 is associated with acute myeloid leukaemia and oesophageal carcinoma [24, 25]. KPNA4 is responsible for prostate cancer metastasis [26]. IPO5 belongs to the karyopherin protein family and usually transports RNA or protein into the nucleus by binding to the nuclear localization signal (NLS) sequence. However, unlike the other karyopherin members, IPO5 has been rarely reported in tumours. Until now, existing studies have shown that IPO5 can mediate the nuclear translocation of the HPV-16 E5 oncoprotein, a virus-associated protein that may be involved in cervical carcinogenesis [27]. Additionally, IPO5 mRNA was reported to be a target of miRNA produced by human herpesvirus 8, a process that may be associated with Kaposi’s sarcoma [28]. Additionally, IPO5 mediates the transport of histones H3, H4, and the ribosomal protein L7 and participates in ribosome synthesis [29]. Moreover, IPO5 can bind to SMAD1 to regulate BMP signalling [30]. These findings, together with our previous database analysis, suggest that IPO5 may play a role in oncogenesis. To our knowledge, this report is the first to elaborate that the altered expression of IPO5 is accompanied by the progression of CRC.

Since preceding studies have shown that the carcinogenic role of karyopherins is attributed to the abnormal transport of cargo proteins [31–33], we hypothesized that the increased nuclear import of IPO5 cargo proteins may be the cause of the observed oncogene phenotype. Here, CO-IP technology followed by mass spectrometry was utilized to search for IPO5 cargo proteins in CRC cells. Many proteins detected have been previously shown to interact with IPO5. The global evaluation of the biological processes of the putative IPO5 cargo revealed several biological pathways, such as viral cell cycle and mRNA metabolic process, which agree with the historical data. This indicates some credibility of the mass spectrometry results, which may facilitate our search for the cargo proteins of IPO5. Then, by analysing the 640 proteins from the mass spectrometry data using the cNLS mapper tool [34, 35] and the COMPARTMENTS database coupled with subsequent
Fig. 6 (See legend on next page.)
Subcellular fractionation methods, we found that RASAL2 may be one of the cargos transported by IPO5 in CRC cells. RASAL2 is a RAS-GTPase-activated protein and a negative regulator of the RAS cascade. Its potential oncosuppressor role was currently hypothesized in a variety of tumors by inhibiting the activation of the downstream RAS pathway [36, 37]. Existing studies have observed that RASAL2 is mainly localized and plays a role in the cytoplasm [38, 39], but whether it could enter the nucleus has not been reported. Here, via immunofluorescence and immunohistochemical staining combined with protein localization database results, we found that RASAL2 is distributed not only in the cytoplasm but also in the nucleus and membranes of CRC cells. This led us to analyze its amino acid sequence by using a related database, and we found that it contains one NLS sequence, which indicates that RASAL2 is very likely to enter the nucleus with the NLS sequence. Therefore, we hypothesized that IPO5 may interact with the NLS of RASAL2, resulting in RASAL2 nuclear translocation and eliminating the inhibitory effect of RASAL2.

Fig. 6 IPO5-mediated nuclear import of RASAL2 is required for RAS pathway activation and CRC development.

a Western blotting was used to determine the expression of ERK, p-ERK, AKT, and p-AKT upon knockdown or overexpressing of IPO5 in CRC cells.

b The NLS mutant of RASAL2 resulted in reversing the IPO5-mediated RAS signaling activation showed by Western blotting.

c and d The recovery effect of NLS mutant on the IPO5-mediated CRC cells migration and proliferation ability were detected by colony formation and transwell respectively. Scale bars, 200 μm.

e Subcutaneous tumorigenesis in nude mice was applied to explore the impact of NLS mutant on tumorigenicity of IPO5 in vivo. Data represent the mean ± SD of 3 independent experiments. *P < 0.05.

f Tumor xenograft tissues were embedded in paraffin and then assessed for the expression of Ki-67 and RASAL2. Scale bars, 200 μm.

g Correlation of nuclear RASAL2 expression and IPO5 expression in colorectal cancer tissue was evaluated by Immunohistochemical. Scale bars, 50 μm.

Fig. 7 Illustration of IPO5 involvement in CRC. IPO5 interacts with the NLS sequence of RASAL2 leading to RASAL2 nuclear transposition, This preventing RASAL2 from functioning as a RAS signaling pathway suppressor in the cytoplasm. Thus resulting in RAS signal activation and CRC growth and metastasis.
in the cytoplasm; this would subsequently augment the RAS pathway and would ultimately drive CRC progression. To validate this hypothesis, we constructed a RASAL2 NLS sequence plasmid with point mutations and transfected cells for further functional experiments. Our results show that the NLS mutations of RASAL2 disrupted the interaction between IPO5 and RASAL2 and significantly impaired the IPO5-mediated malignant characteristics of CRC. There is evidence that some karyopherins share common cargo [40, 41], and this is coupled with the fact that our exploration for the IPO5 binding cargo still lacks specificity; therefore, we must bear in mind that is a possibility that RASAL2 enters the nucleus, which is also mediated by other IPO5 family members. These results invite us to carry out further studies. Because altered karyopherin protein functions play a vital role in drug resistance [42, 43], recent studies point to their potential usefulness as a novel strategy for anticancer therapy [44]. A small molecule inhibitor targeting CRM1 has been shown to be beneficial to the anticancer effects [45–47]. INI-1, an inhibitor of KPNB1, is a potent chemotherapeutic agent of malignancies [48]. However, because normal cells also share the nuclear transport machinery with cancer cells, drugs targeting these proteins are currently limited. Therefore, prospective basic research with regard to the tumorigenic mechanisms of karyopherin proteins is lacking and is desperately required for effective cancer therapy.

Conclusions
In summary, the current study demonstrated that IPO5 is an oncogene involved in CRC cell proliferation and migration. This highlights the significance of IPO5 in 5-fluorouracil-resistant CRC cells. The oncogenic function of IPO5 was mediated by promoting RAS signalling by increasing the nuclear translocation of RASAL2 (Fig. 7). Our results provide new information on the carcinogenic role mediated by IPO5. It is expected to be a promising therapeutic target.

Additional files

Additional file 1: Figure S1. The expression of IPO5, data from public database. (A) Analysis of IPO5 expression in different types of malignancies. (B) Analysis of IPO5 expression in TCGA CRC large sample genomic database. (C) Analysis of IPO5 expression using the CRC gene expression profile data GSE41258. (JPG 849 kb)

Additional file 2: Figure S2. Effects of IPO5 over-expression on CRC cell proliferation and migration in vitro (A and B) Up-regulation of IPO5 increased cell proliferation (P < 0.01) and clonogenicity (P < 0.01) as compared to controls. (C) The effect of IPO5 on the cell cycle distribution was detected by flow cytometry in CRC cells. (D) The impact of ectopic expression of IPO5 on cell migration was validated by transwell assay (P < 0.01). (E) Screen out IPO5 transporting cargos using subcellular fractionation methods followed by immunoblotting. (JPG 5002 kb)

Additional file 3: Table S1. List of IPO5 binding candidates identified by mass spectrometry. (DOCX 55 kb)

Additional file 4: Table S2. Pathway analysis of IPO5 binding candidates using DAVID tool. (DOCX 16 kb)

Additional file 5: Table S3. List of 15 IPO5 binding proteins with NLS sequence. (DOCX 20 kb)

Additional file 6: Table S4. Primer sequences used in RT-qPCR analysis. Table S5: Nucleotide sequences used for knockdown. (DOC 40 kb)

Abbreviations
5-FU: 5-fluorouracil; BSA: Albumin from bovine serum; CCK-8: Cell counting kit-8; CO-IP: Co-Immunoprecipitation; CRC: Colorectal cancer; CRM1: Exportin CRM1; FBS: Fetal bovine serum; IF: Immunofluorescence; IHC: Immunohistochemistry; IPO5: Importin 5; M5: Mass spectrometry; NC: Negative control; NLS: Nuclear localization sequence; NPC: Nuclear pore complex; qPCR: Quantitative real-time polymerase chain reaction; RASAL2: RAS protein activator like 2; TCGA: The Cancer Genome Atlas; TNM: Tumor Node Metastasis

Acknowledgements
Not applicable.

Authors’ contributions
XNL contributed to study design, analysis, obtaining funding, study supervision. WJZ carried out the experiments and writing up the manuscript. YXL and WXL contributed in data acquisition, analysis, and interpretation of the data. JMZ and WZ contributed in statistical analysis. WHL contributed in the collection of patient samples and clinical input. All authors read and approved the final manuscript.

Funding
This study was supported by the National Natural Science Foundation of China (grant numbers 81874074, 81672429 and 81502479).

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was approved by the Ethics Committees of Nanfang Hospital, Southern Medical University. Written informed consent was obtained from all patients.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing financial interests in our study.

Author details
1Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, People’s Republic of China.
2Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Received: 22 January 2019 Accepted: 25 June 2019
Published online: 09 July 2019

References
1. Chook YM, Blobel G. Karyopherins and nuclear import. Curr Opin Struct Biol. 2001;11:703–15.
2. Çağatay T, Chook YM. Karyopherins in cancer. Curr Opin Cell Biol. 2018; 52:30–42.
3. Lund E, Guttinger S, Calado A, Dahlberg JE, Katuy U. Nuclear export of microRNA precursors. Science. 2004;303:95–8.
4. Silver PA, Kau TR, Way JC. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer. 2004;4:106–17.
Soniat M, Cagatay T, Chook YM. Recognition elements in the histone H3.

Krawczyk E, Hanover JA, Schlegel R, Suprynowicz FA. Karyopherin beta3: a nuclear transport protein.

Angus L, van der Watt PJ, Leaner VD. Inhibition of the nuclear transporter, Nup153.

Kojima K, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE, et al. Cancer-derived exosomal proteins attenuate prostate cancer metastasis.

Li J, Liu Q, Liu Z, Xia Q, Zhang J, Zhang R, et al. KPNA2 promotes metabolic reprogramming in glioblastomas by regulation of c-myc.

Kim J, McMillan E, Kim HS, Venkateswaran N, Makkar G, Rodriguez-Canales J, et al. Expression, function, and localization of importin beta-1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation.

Shigeyasu K, Okugawa Y, Toden S, Boland CR, Goel A. Exportin-5 functions as an oncogene and a potential therapeutic target in colorectal cancer.

Zhang et al. Journal of Experimental & Clinical Cancer Research.

New cellular target for the HPV-16 E5 oncoprotein.

Attenuates prostate cancer metastasis. Oncogene. 2013;32:6867–709.

Duan J, Tang Z, Yu H, Zhang G. [retracted] nuclear import of prototype protein receptor SMAD-specific importin. J Biol Chem. 2016;291:24121–32.

PloS One. 2013;8:e76864.

Cancer Cell. 2015;112:1929–37.

Leukemia. 2014;28:155–63.

Cancer. 2015;112:1929–37.

Cancer. 2017;7:202–17.

Cancer Res. 2018;25:2323-35.

Nuclear-cytoplasmic transport is a therapeutic target in myelofibrosis. Clin Cancer Res. 2018;24:24121–32.

Cells. 2018;7:221.

Recognition elements in the histone H3 and H4 tails for seven different importins.

Identification of target genes regulated by KSHV mRNAs in KSHV-infected lymphoma cells.

van der Watt PJ, Chi A, Stelma T, Stowell C, Strydom E, Carden S, et al. Targeting the nuclear import receptor Kpnbeta1 as an anticancer therapeutic. Mol Cancer Ther. 2016;15:560–73.